1620 Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

1620 Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.4K	Hold	1,577	–	–	0.03%	319
2026 Q1	$47.5K	Hold	1,577	–	–	0.03%	311
2025 Q4	$49.2K	Buy	1,577 +1,495	+1,823%	+$36.8K	0.03%	304
2025 Q3	$1.66K	Hold	82	–	–	﹤0.01%	597
2025 Q2	$1.37K	Hold	82	–	–	﹤0.01%	622
2025 Q1	$1.26K	Hold	82	–	–	﹤0.01%	613
2024 Q4	$1.81K	Hold	82	–	–	﹤0.01%	591
2024 Q3	$1.48K	Sell	82 -18	-18%	-$315	﹤0.01%	585
2024 Q2	$1.63K	Buy	+100	New	+$1.54K	﹤0.01%	555

Other funds holding TEVA

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

1620 Investment Advisors's TEVA Position: Q2 2026 in Review

1620 Investment Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 1,577 shares worth $53.4K. The position accounts for 0.03% of the portfolio, ranked #319.

1620 Investment Advisors first reported a position in TEVA in Q2 2024 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

1620 Investment Advisors held 1,577 shares of Teva Pharmaceuticals worth $53.4K as of Q2 2026.
1620 Investment Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.03% of 1620 Investment Advisors's portfolio in Q2 2026, its #319 holding.
1620 Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
183 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.